Glutamate-based depression GBD

Medical Hypotheses

Volumn 78, Issue 5, 2012, Pages 675-681

  McCarthy, Dennis J ^a   Alexander, Robert ^a   Smith, Mark A ^a   Pathak, Sanjeev ^a   Kanes, Stephen ^a   Lee, Chi Ming ^b   Sanacora, Gerard ^c  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ARTICLE; BRODMANN AREA 25; CHRONIC DISEASE; CINGULATE GYRUS; COMORBIDITY; DEPRESSION; ENVIRONMENTAL STRESS; GLUTAMATE BASED DEPRESSION; HUMAN; HYPOTHESIS; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; RECEPTOR UPREGULATION; RISK FACTOR; SYMPTOMATOLOGY;

AFFECT; ALZHEIMER DISEASE; ARTHRITIS, RHEUMATOID; CHRONIC PAIN; COGNITION; CORONARY ARTERY DISEASE; DEPRESSION; DIABETES COMPLICATIONS; FIBROMYALGIA; GLUTAMIC ACID; GYRUS CINGULI; HUMANS; HUNTINGTON DISEASE; INFLAMMATION; INTERFERONS; MODELS, NEUROLOGICAL; MODELS, PSYCHOLOGICAL; PARKINSON DISEASE; RECEPTORS, N-METHYL-D-ASPARTATE; RISK FACTORS; STROKE; SYNAPTIC TRANSMISSION;

EID: 84862778539     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.02.009     Document Type: Article

References (106)

1. Sanacora G., Treccani G., Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmcol 2012, 62:63-77.
2. Marsden W.N. Stressor-induced NMDAR dysfunction as a unifying hypothesis of the aetiology, pathogenesis and comorbidity of clinical depression. Med Hypotheses 2011, 77:508-528.
3. Niciua MJ, Kelmendic B, Sanacora G. Overview of glutamatergic neurotransmission in the nervous system. Pharmacol Biochem Behav, in Press, uncorrected proof. doi:10.1016/j.pbb.2011.08.008.
4. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009, 61:105-123.
5. Pittenger C., Sanacora G., Krystal J.H. The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets 2007, 6:101-115.
6. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999, 375:31-40.
7. Musazzi L., et al. Acute stress increases depolarization-evoked glutamate release in the Rat prefrontal/frontal cortex: the dampening action of antidepressants. PLoS One 2010, 5:e8566.
8. Reznikov L.R., Grillo C.A., Piroli G.G., et al. Acute stress-mediated increases in extracellular glutamate levels in the rat amygadala: differential effects of antidepressant treatment. Eur J Neurosci 2007, 25(10):3109-3114.
9. Kasper S., McEwen B.S. Neurobiological and clinical effects of the antidepressant tianeptine. CNS Drugs 2008, 22:15-26.
10. McEwen B.S., Chattarji S., Diamond D.M., et al. The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry 2010, 15:237-249.
11. Trullas R., Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990, 185:1-10.
12. Kotlinska J., Bochenski M. The influence of various glutamate receptors antagonists on anxiety-like effect of ethanol withdrawal in a plus-maze test in rats. Eur J Pharmacol 2008, 598:57-63.
13. Gatch M.B., Wallis C.J., Lal H. Effects of NMDA antagonists on ethanol withdrawal induced " anxiety" in the elevated plus maze. Alcohol 1999, 19:207-211.
14. Carroll R.C., Zukin R.S. NMDA-receptor trafficking and targeting: implications for synaptic transmission and plasticity. Trends Neurosci 2002, 25:571-577.
15. Banasr M., Chowdhury G.M., Terwilliger R., et al. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 2010, 15:501-511.
16. Nie H., Zhang H., Weng Han-Rong Bidirectional neuron - Glia interactions triggered by deficiency of glutamate uptake at spinal sensory synapses. J Neurophysiol 2010, 104:2713-2725.
17. Hardingham G.E., Bading H. Synaptic versus extrasynaptic NMDA receptor signaling: implications for neurodegenerative disorders. Nat Rev Neurosci 2010, 11:682-696.
18. Lowy M.T., Wittenberg L., Yamamoto B.K. Effect of acute stress on hippocampal glutamate levels and spectrin proteolysis in young and aged rats. J Neurochem 1995, 65:268-274.
19. Paul I.A., Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann NY Acad Sci 2003, 1003:250-272.
20. Hashimoto K., Sawa A., Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007, 62:1310-1316.
21. Mayberg H.S., Lozano A.M., Voon V., Mc Neely H.E. Deep brain stimulation for treatment-resistant depression. Neuron 2005, 45:651-660.
22. Liotti M., Mayberg H.S., Brannan S.K., McGinnis S., Jerabek P., Fox P.T. Differential limbic-cortical correlates of sadness and anxiety in healthy subjects: implications for affective disorders. Biol Psychiatry 2000, 48:30-42.
23. Agid Y., Buzsaki G., Diamond D.M., Frackowiak R., Giedd J., Weinberger D., et al. How can drug discovery for psychiatric disorders be improved?. Nat Rev Drug Discov 2007, 6:189-201.
24. Rota M., Collins K.A., Murrough J.W., Perezb A.M., Reichb D.L., Charney D.S., et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010, 67:139-145.
25. Zarate C.A., Singh J.B., Carlson P.J., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.
26. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
27. Deakin J.F.W., Lees J., McKie S., Hallak J.E.C., Williams S.R., Dursun S.M. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 2008, 65:154-164.
28. Hertz L., Zielke H.R. Astrocytic control of glutamatergic activity: astrocytes as stars of the show. Trends Neurosci 2004, 27(2004):735-743.
29. Bunch L., Erichsen M.N., Jensen A.A. Excitatory amino acid transporters as potential drug targets. Expert Opin Ther Targets 2009, 13:719-731.
30. Banasr M., Duman R. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry 2008, 64:863-870.
31. Zou J.Y., Crews F.T. TNF-alpha potentiates glutamate neurotoxicity by inhibiting glutamate uptake in organotypic brain slice cultures: neuroprotection by NF kappa B inhibition. Brain Res 2005, 1034:11-24.
32. Ongur D., Drevets W.C., Price J.L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998, 95:13290-13295.
33. Rajkowska G., Miguel-Hidalgo J.J. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007, 6:219-233.
34. Preskorn S., Baker B., Kolluri S., Menniti F.S., Krams M., Landen J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 2008, 28:631-637.
35. Li N., Lee B., Liu R.J., Banasr M., et al. MTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
36. Maeng S., Zarate C.A., Du J., et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008, 63:349-352.
37. Dybala M., Siwek A., Poleszak E., Pilc A., Nowak G. Lack of NMDA-AMPA interaction in antidepressant-like effect of CGP 37849, an antagonist of NMDA receptor, in the forced swim test. J Neural Transm 2008, 115:1519-1520.
38. Pizzagalli D.A., Oakes T.A., Fox A.S., et al. Functional but not structural subgenual prefrontal cortex abnormalities in melancholia. Mol Psychiatry 2004, 9:393-405.
39. Schatzberg A.F., Posener J.A., DeBattista C., Kalehzan B.M., Rothschild A.J., Shear P.K. Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. Am J Psychiatry 2000, 157:1095-1100.
40. Segal S, Tetens J, Kegeles L, et al., The effects of local high frequency electrical stimulation on monoamine efflux in the subgenual cingulate cortex (Brodmann Area 25) and its striatal and thalamic projection regions, 37th annual meeting of the Society for Neuroscience 2007 Poster 267.22/W1.
41. Salvadore G., Cornwell B.R., Colon-Rosario V., Coppola R., Grillon C., Zarate C.A.I Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 2009, 65:289-295.
42. Salvadore G, Cornwell BR, Sambataro F, et al., Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine, Neuropsychopharmacology March 2010, pp. 1-8, Advanced online publication.
43. Harrison N.A., Brydon L., Walker C., Gray M.A., Steptoe A., Critchley H.D. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 2009, 66:407-414.
44. Popoli M., Yan Z., McEwen B.S., Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci 2012, 13:22-37.
45. Müller N., Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 2007, 12:988-1000.
46. Piani D., Frei K., Do K.Q., Cuenod M., Fontana A. Murine brain macrophages induce NMDA receptor mediated neurotoxicity by secreting glutamate. Neurosci Lett 1991, 133:159-162.
47. Hu S., Sheng W.S., Ehrlich L.C., Peterson P.K., Chao C.C. Cytokine effects on glutamate uptake by human astrocytes. Neuroimmunomodulation 2000, 7:153-159.
48. Carmen J., Rothstein J.D., Kerr D.A. Tumor necrosis factor-alpha modulates glutamate transport in the CNS and is a critical determinant of outcome from viral encephalomyelitis. Brain Res 2009, 1263:143-154.
49. Tolosa L., Caraballo-Miralles V., Olmos G., Lladó J. TNF-α potentiates glutamate-induced spinal cord motoneuron death via NF-κB. Mol Cell Neurosci 2011, 46:176-186. Epub 2010.
50. Wolkowitz O.M., Mellon S.H., Epel E.S., et al. Leukocyte telomer length in major depression: correlations with chronicity, inflammation and oxidative stress-Preliminary findings. PLoS ONE 2011, 6:1-7.
51. Schaefer M., Schwaiger M., Pich M., Lieb K., Heinz A. Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry 2003, 36:203-206.
52. Glassman A.H., Bigger J.T., Gaffney M., Swenson J.R. Onset of major depression associated with acute coronary syndromes. Arch Gen Psychiatry 2006, 63:283-288.
53. Frasure-Smith N., Lespérance F. Recent evidence linking coronary heart disease and depression. Can J Psychiatry 2006, 51:730-737.
54. Lespérance F., Frasure-Smith N., Koszycki D., et al. The CREATE Investigators. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) Trial. JAMA 2007, 297:367-379.
55. L.R. Wulsin, Treating the Aching Heart, Vanderbilt University Press, 2007.
56. Carney R.M., Freedland K.E. Does treating depression improve survival after acute coronary syndrome?. Br J Psychiatry 2007, 190:467-468.
57. Wirleitner B., Rudzite V., Neurauter G., et al. Immune activation and degradation of tryptophan in coronary heart disease. Eur J Clin Invest 2003, 33:550-554.
58. Wichers M.C., Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-α-induced depression. J Psychiatry Neurosci 2004, 29:11-17.
59. Wang L., Piserchio A., Mierke D.F. Structural characterization of the intermolecular interactions of synapse-associated protein-97 with the NR2B subunit of the N-Methyl-d-aspartate receptors. J Biol Chem 2005, 280:26992-26996.
60. Dickens C., Creed F. The burden of depression in patients with rheumatoid arthritis. Rheumatology 2002, 40:1327-1330.
61. Dickens C., McGowan L., Clark-Carter D., Creed F. Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med 2002, 64:52-60.
62. Katz P.P., Yelin E.H. Prevalence and correlates of depressive symptoms among persons with rheumatoid arthritis. J Rheumatol 1993, 20:790-796.
63. Ang D.C., Choi H., Kroenke K., Wolfe F. Co-morbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol 2005, 32:1013-1019.
64. Timonen M., Viilo K., Hakko H. Suicides in persons suffering from rheumatoid arthritis. Rheumatology 2003, 42:287-291.
65. Treharne G., Lyons A.C., Kitas G.D. Suicidal ideation in patients with rheumatoid arthritis. Research may help identify patients at high risk. BMJ 2000, 321:1290-1297.
66. Parada-Turskaa J., Rzeskib W., Majdana M., Kandefer-Szerszeńb M., Turskic W. Effect of glutamate receptor antagonists and antirheumatic drugs on proliferation of synoviocytes in vitro. Eur J Pharmacol 2006, 535:95-97.
67. Yoshihara Y., Nakamura H., Obata K., Yamada H., Hayakawa T., Fujikawa K. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatooid arthritis or osterarthritis. Ann Rheum Dis 2000, 59:455-461.
68. Flood S., Parri R., Williams A., Duance V., Mason D. Modulation of interleukin-6 and matrix metalloproteinase 2 expression in human fibroblast-like synoviocytes by functional ionotropic glutamate receptors. Arthritis Rheum 2007, 56:2523-2534.
69. Domenici E, Willé DR, Tozzi F, et al., Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections, PLoS ONE 2010;5:1-12. www.plosone.org.
70. Arnow B.A., Hunkeler E.M., Blasey C.M., et al. Co-morbid depression, chronic pain, and disability in primary care. Psychosom Med 2006, 68:262-268.
71. Munce S.E., Stewart D.E. Gender differences in depression and chronic pain conditions in a national epidemiologic survey. Psychosomatics 2007, 48:394-399.
72. Bleakman D., Alt A., Nisenbaum E.S. Glutamate receptors and pain. Semin Cell Dev Biol 2006, 17:592-604.
73. Zhuo M. Glutamate receptors and persistent pain: targeting forebrain NR2B subunits. Drug Discov Today 2002, 7:259-267.
74. Buchheit T., Pyati S. Efficacy and safety of ketamine in patients with complex regional pain syndrome: a systematic review. CNS Drugs 2011, 4:4-7. Epub ahead of print. 10.2165/11595200.
75. McGuinness S.K., Wasiak J., Cleland H., Symons J., Hogan L., Hucker T., et al. A systematic review of ketamine as an analgesic agent in adult burn injuries. Pain Med 2011, 12(10):1551-1558. Epub 2011. 10.1111/j.1526-4637.2011.01220.x.
76. Hocking G., Cousins M.J. Ketamine in chronic pain management: an evidence-based review. Anesth Analg 2003, 97:1730-1739.
77. Goldney R.D., Phillips P.J., Fisher L.J., Wilson D.H. Diabetes, depression and quality of life: a population study. Diabetes Care 2004, 27:1066-1070.
78. Hack V., Stiitz O., Kinscherf R., Schykowski M., Kellerer M., Holm E., et al. Elevated venous glutamate levels in (pre)catabolic conditions result at least partly from a decreased glutamate transport activity. J Mol Med 1996, 74:337-343.
79. Li Q., Puro D.G. Diabetes-induced dysfunction of the glutamate transporter in retinal muller cells. IOVS 2002, 43:3109-3116.
80. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004, 27:813-823.
81. Yoon YH, Yoo AM, Koh JY, Riluzole inhibits retinal endothelial cell proliferation in vivo and in vitro, Invest Ophthalmol Vis Sci 2004; 45:E-Abstract 454.
82. Brott T., Bogousslavsky J. Drug therapy: treatment of acute ischemic stroke. N Engl J Med 2000, 343:710-722.
83. Choi D.W., Rothman S.M. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 1990, 13:171-182.
84. Bullock R., Zauner A., Woodward J., Young H.F. Massive persistent release of excitatory amino acids following human occlusive stroke. Stroke 1995, 26:2187-2189.
85. Dávalos D., Castillo J., Serena J., Noya M. Duration of glutamate release after acute ischemic stroke. Stroke 1997, 28:708-710.
86. Gordon W.A., Hibbard M.R. Post-stroke depression: an examination of the literature. Arch Phys Med Rehabil 1997, 78:658-663.
87. Hazell A.S. Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies. Neurochem Int 2007, 50:941-953.
88. Rossi D.J., Brady J.D., Mohr C. Astrocyte metabolism and signaling during brain ischemia. Nat Neurosci 2007, 10:1377-1386.
89. Lyketsos C.G., Steele C., Baker L., et al. Major and minor depression in Alzheimer's disease: prevalence and impact. J Neuropsychiatry Clin Neurosci 1997, 9:556-561.
90. Maragos W.F., Greenamyre J.T., Penney J.B., Young A.B. Glutamate dysfunction in Alzheimer's disease: an hypothesis. Trends Neurosci 1987, 10:65-68.
91. Hughes T.A., Ross H.F., Mindham R.H.S., Spokes E.G.S. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004, 110:118-123.
92. Marino M.J., Valenti O., Conn P.J. Glutamate receptors and Parkinson's disease: opportunities for intervention. Drugs Aging 2003, 20:377-397.
93. Benabid A.L., Pollak P., Louveau A., de Rougemont J., Henry S. Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease. Appl Neurophysiol 1987, 50:344-346.
94. Follett K.A., Weaver F.M., Stern M., et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010, 362:2077-2091.
95. van Duijn E.M., Kingma R.C., Mast Van der Psychopathology in verified Huntington's disease gene carriers. J Neuropsychiatry Clin Neurosci 2007, 19:441-448.
96. Arzberger T., Krampfl K., Leimgruber S., Weindl A. Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's Disease - An in-situ hybridization study. J Neuropathol Exp Neurol 1997, 56:440-454.
97. Okamoto S., et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 2009, 15:1407-1413.
98. Thu D.C., Oorschot D.E., Tippett L.J., et al. Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. Brain 2010, 133:1094-1110.
99. Wolfe F., Smythe H.A., Yunus M.B., et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990, 33:160-172.
100. Aaron L.A., Bradley L.A., Alarcon G.S., Alexander R.W., Triana-Alexander M., Martin M.Y., et al. Psychiatric diagnoses in patients with fibromyalgia are related to health care-seeking behavior rather than to illness. Arthritis Rheum 1996, 39:436-445.
101. Hudson J.I., Goldenberg D.L., Pope H.G., Keck P.E., Schlesinger L. Co-morbidity of fibromyalgia with medical and psychiatric disorders. Am J Med 1992, 92(4):363-367.
102. Sarchielli P., Di Filippo M., Nardi K., Calabresi P. Sensitization, glutamate, and the link between migraine and fibromyalgia. Curr Pain Headache Rep 2007, 11:343-351.
103. Smith J.D., Terpening C.M., Schmidt S.O.F., Gums J.G. Relief of fibromyalgia symptoms following discontinuation of dietary excitotoxins. Ann Pharmacother 2001, 35:702-706.
104. Sörensen J., Bengtsson A., Bäckman E., Henriksson K.G., Bengtsson M. Pain analysis in patients with fibromyalgia: effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol 1995, 24:360-365.
105. Nicolodi M., Volpe A.R., Sicuteri F. Fibromyalgia and headache. Failure of serotonergic analgesia and N-methyl-d-aspartate-mediated neuronal plasticity: their common clues. Cephalalgia 1998, 18:41-44.
106. Nielsen T.G., Aspegren K.S., Henriksson K.G., et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain 2000, 85:483-491.